trans-1-<2-(4-amino-1,3-dimethyl-1H-pyrazol-5-yl)-4,5-dihydro-4,5-dimethyl-1H-imidazol-1-yl>ethanone | 111770-53-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: trans-1-<2-(4-amino-1,3-dimethyl-1H-pyrazol-5-yl)-4,5-dihydro-4,5-dimethyl-1H-imidazol-1-yl>ethanone
• 英文别名: 1-[(4R,5R)-2-(4-amino-2,5-dimethylpyrazol-3-yl)-4,5-dimethyl-4,5-dihydroimidazol-1-yl]ethanone
• CAS: 111770-53-7
• 化学式: C₁₂H₁₉N₅O
• 分子量: 249.316
• InChiKey: IEXOGOVKPORSNV-HTRCEHHLSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  18.0
• 可旋转键数：
  1.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.58
• 拓扑面积：
  76.51
• 氢给体数：
  1.0
• 氢受体数：
  5.0

反应信息

• 作为反应物：
  描述：

  trans-1-<2-(4-amino-1,3-dimethyl-1H-pyrazol-5-yl)-4,5-dihydro-4,5-dimethyl-1H-imidazol-1-yl>ethanone 生成 trans-7,8-dihydro-1,3,5,7,8-pentamethyl-1H-imidazo<1,2-c>pyrazolo<3,4-e>pyrimidine
  参考文献：
  名称：

  DEWALD, HORACE A.;BEESON, NICHOLAS W.;HERSHENSON, FRED M.;WISE, LAWRENCE +, J. MED. CHEM., 31,(1988) N 2, 454-461

  摘要：

  DOI：
• 作为产物：
  描述：

  5-(4,5-dihydro-4,5-dimethyl-1H-imidazol-2-yl)-1,3-dimethyl-4-nitro-1H-pyrazole 在 palladium on activated charcoal 氢气 、 三乙胺 作用下， 以 二氯甲烷 、 溶剂黄146 为溶剂， 25.0 ℃ 、344.73 kPa 条件下， 反应 4.0h， 生成 trans-1-<2-(4-amino-1,3-dimethyl-1H-pyrazol-5-yl)-4,5-dihydro-4,5-dimethyl-1H-imidazol-1-yl>ethanone
  参考文献：
  名称：

  Synthesis and potential antipsychotic activity of 1H-imidazo[1,2-c]pyrazolo[3,4-e]pyrimidines

  摘要：

  The synthesis of a series of 1H-imidazo[1,2-c]pyrazolo[3,4-e]pyrimidines is reported along with the effects of these compounds in preclinical tests for antipsychotic activity. Certain of these compounds displayed antipsychotic-like effects in conditioned avoidance tests, but unlike currently used antipsychotic drugs, they did not have affinity for brain dopamine receptors. These compounds also did not cause dystonias predictive of extrapyramidal side effects in monkeys at doses that produced behavioral effects. On the basis of this unique biological profile, a member of this series 7,8-dihydro-8-ethyl-1,3,5-trimethyl-1H-imidao[1,2-c]pyrazol[3,4-e] pyrimidine (19, CI-943), has been selected for clinical evaluation as an antipsychotic agent.

  DOI：

  10.1021/jm00397a032